IP Library Granted Patent US 11,117,862
Granted Patent B2
US 11,117,862 · App. 16/863,020 · Granted Sep 14, 2021

Methods of producing molindone and its salts

Inventors: Martin Hanbauer (Regensburg, DE); Zarghun Nazir (Linz, AT); Peter Hildebrand (Linz, AT); Attilia Figini (Rancate, CH); Likan Liang (Boyds, MD); Tiziano Fumagalli (Pianello del Lario, IT)
Assignee: Supernus Pharmaceuticals, Inc.
C07D209/08C07D295/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,117,862
App. No.
16/863,020
Granted
Sep 14, 2021
Kind
B2
Abstract

The present invention is directed towards novel methods of synthesis of molindone, synthesis of the intermediates of molindone, and high-purity compositions of molindone. In particular, the invention relates to the methods of synthesis of molindone through the Mannich reaction.

Claims (8)

1. A composition comprising molindone or its pharmaceutically acceptable salt as the sole active ingredient, formaldehyde, and 2,3-pentanedione-2,3-dioxime.

2. A composition comprising molindone or its pharmaceutically acceptable salt as the sole active ingredient, formaldehyde, 2,3-pentanedione-2,3-dioxime, and acetaldehyde oxime.

3. A composition comprising molindone or its pharmaceutically acceptable salt as the sole active ingredient and 2,3-pentanedione-2,3-dioxime.

4. A composition comprising molindone or its pharmaceutically acceptable salt as the sole active ingredient, 2,3-pentanedione-2,3-dioxime, and acetaldehyde oxime.

5. A composition comprising molindone or its pharmaceutically acceptable salt as the sole active ingredient, 2,3-pentanedione-2,3-dioxime, acetaldehyde oxime, and 1-hydroxy-propan-2-one oxime.

6. A composition comprising molindone or its pharmaceutically acceptable salt as the sole active ingredient and acetaldehyde oxime.

7. A composition comprising molindone or its pharmaceutically acceptable salt as the sole active ingredient, acetaldehyde oxime, and 1-hydroxy-propan-2-one oxime.

8. A composition comprising molindone or its pharmaceutically acceptable salt as the sole active ingredient and 1-hydroxy-propan-2-one oxime.

Continuity (7)
Division 16107836 · Aug 21, 2018
Continuation 15723515 · Oct 3, 2017
Continuation 15365566 · Nov 30, 2016
Continuation 14608262 · Jan 29, 2015
Division 13834097 · Mar 15, 2013
Provisional Application 61701007 · Sep 14, 2012
Related Publication 20200262789A1 · Aug 20, 2020